Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.
Last week, Medicus Pharma announced the submission of an orphan drug designation (ODD) application to the FDA for SkinJect (D-MNA), a novel intradermal therapy under development for the treatment of basal cell carcinoma (BCC) in patients with Gorlin syndrome.1 The application marks a strategic expansion of the SkinJect program into a rare dermatologic condition with no approved targeted therapies and significant unmet clinical need.
Gorlin syndrome, also known as nevoid BCC syndrome, is a rare autosomal dominant disorder most commonly associated with mutations in the PTCH1 gene. These mutations dysregulate the Hedgehog signaling pathway, driving early-onset, continuous development of multiple BCCs. Patients frequently develop dozens to hundreds—and in some cases, more than 1000—cutaneous tumors over their lifetime, often beginning in childhood or adolescence. The chronic and recurrent nature of the disease requires repeated interventions, most commonly surgical excision or Mohs micrographic surgery, which can lead to cumulative morbidity, scarring, and psychosocial burden.
Despite the significant disease impact, there are currently no FDA-approved therapies specifically indicated for BCC in Gorlin syndrome. Systemic Hedgehog pathway inhibitors have demonstrated efficacy in advanced or metastatic BCC. However, their use is often limited by tolerability concerns and high rates of tumor recurrence upon treatment discontinuation. As a result, there remains a need for alternative, lesion-directed therapies that can be used repeatedly and safely over time.
SkinJect is being developed to address this gap through a localized, minimally invasive approach. The investigational therapy consists of a dissolvable microneedle array containing doxorubicin, designed to deliver the chemotherapeutic agent directly into the dermis at the tumor site. Upon application, the microneedles penetrate the skin and dissolve in situ, releasing the drug into the lesion. This targeted delivery system enables high local drug concentrations while minimizing systemic exposure.
Mechanistically, SkinJect is intended to exert both direct cytotoxic effects on tumor cells and to induce immunogenic cell death, potentially stimulating a localized immune response. This dual mechanism may be particularly advantageous in Gorlin syndrome, where patients require ongoing treatment of multiple lesions across different anatomical sites.
Clinical data supporting SkinJect’s development have been generated in
The submission for ODD is supported by epidemiologic data indicating that Gorlin syndrome affects approximately 11,000 individuals in the US, which is well below the threshold of 200,000 patients that is required for orphan status. If granted, the designation would provide several regulatory and commercial incentives, including 7 years of market exclusivity upon approval, potential tax credits for clinical development, a waiver of certain FDA fees, and opportunities for enhanced regulatory engagement.
From a strategic perspective, the ODD application reinforces Medicus Pharma’s broader development plan for SkinJect as a platform technology in nonmelanoma skin cancers. In addition to its orphan indication strategy, SkinJect is positioned as a potentially repeatable, nonsurgical alternative to current standards of care. For dermatologists managing patients with Gorlin syndrome, such an option could represent a meaningful shift in treatment paradigms, reducing reliance on repeated surgical procedures and associated complications.
References
1. Medicus Pharma submits orphan drug designation application to US FDA for SkinJect in Gorlin syndrome. News release. Medicus Pharma. April 17, 2026. Accessed April 23, 2026.
2. Medicus Pharma Ltd completes enrolment of ninety (90) patients for phase 2 clinical study (SKNJCT-003) to non-invasively treat basal cell carcinoma (BCC) of the skin. News release. Medicus Pharma. December 15, 2025. Accessed April 23, 2026.
